56R Stock Overview

Through its subsidiaries, focuses on non-invasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals. More details

56R fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 10.3% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap (€3M)

Shareholders have been substantially diluted in the past year

Does not have meaningful revenue ($3M)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

NanoVibronix, Inc. Competitors

Geratherm Medical

XTRA:GME

€17.2m

PULSION Medical Systems

MUN:PUS

€131.9m

NanoRepro

XTRA:NN6

€17.7m

Arzneiwerk VIDA

XTRA:TLIK

€3.8m

Price History & Performance

Summary of share price highs, lows and changes for NanoVibronix
Historical stock prices
Current Share Price	US$6.56
52 Week High	US$13.66
52 Week Low	US$2.20
Beta	2.04
1 Month Change	17.00%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	87.43%

Recent updates

Shareholder Returns

	56R	DE Medical Equipment	DE Market
7D	0%	1.7%	0.7%
1Y	n/a	-9.4%	13.8%

Return vs Industry: Insufficient data to determine how 56R performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how 56R performed against the German Market.

Price Volatility

Is 56R's price volatile compared to industry and market?
56R volatility
56R Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.9%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	12.9%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: 56R's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 56R's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2003	31	Brian Murphy	www.nanovibronix.com

NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures.

NanoVibronix, Inc. Fundamentals Summary

How do NanoVibronix's earnings and revenue compare to its market cap?
56R fundamental statistics
Market cap	€2.79m
Earnings (TTM)	-€3.32m
Revenue (TTM)	€2.29m

1.2x

P/S Ratio

-0.8x

P/E Ratio

Is 56R overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
56R income statement (TTM)
Revenue	US$2.56m
Cost of Revenue	US$1.05m
Gross Profit	US$1.51m
Other Expenses	US$5.21m
Earnings	-US$3.70m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-4.88
Gross Margin	58.95%
Net Profit Margin	-144.84%
Debt/Equity Ratio	0%

How did 56R perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/13 21:48
End of Day Share Price	2025/04/15 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NanoVibronix, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Robert Wasserman	Dawson James Securities
Joseph Gomes	Wm Smith & Co.
Brian Marckx	Zacks Investment Research Inc.

NanoVibronix MUN:56R Stock Report